1. Circulating DNA methylation profile improves the accuracy of serum biomarkers for the detection of nonmetastatic hepatocellular carcinoma.
- Author
-
Phan TH, Chi Nguyen VT, Thi Pham TT, Nguyen VC, Ho TD, Quynh Pham TM, Tran TH, Nguyen TD, Khang Le ND, Nguyen TH, Duong ML, Bach HT, Kim VV, Pham TA, Nguyen BT, Vo Nguyen TN, Nguyen TD, Bieu Phu DT, Huu Phan BH, Nguyen DS, Truong DK, Do TT, Giang H, Nguyen HN, Phan MD, and Tran LS
- Subjects
- Humans, alpha-Fetoproteins metabolism, DNA Methylation, Biomarkers, Biomarkers, Tumor, Sensitivity and Specificity, Carcinoma, Hepatocellular diagnosis, Carcinoma, Hepatocellular genetics, Liver Neoplasms diagnosis, Liver Neoplasms genetics, Liver Neoplasms pathology
- Abstract
Aim: This study exploited hepatocellular carcinoma (HCC)-specific circulating DNA methylation profiles to improve the accuracy of a current screening assay for HCC patients in high-risk populations. Methods: Differentially methylated regions in cell-free DNA between 58 nonmetastatic HCC and 121 high-risk patients with liver cirrhosis or chronic hepatitis were identified and used to train machine learning classifiers. Results: The model could distinguish HCC from high-risk non-HCC patients in a validation cohort, with an area under the curve of 0.84. Combining these markers with the three serum biomarkers (AFP, lectin-reactive AFP, des-γ-carboxy prothrombin) in a commercial test, μTASWako
® , achieved an area under the curve of 0.87 and sensitivity of 68.8% at 95.8% specificity. Conclusion: HCC-specific circulating DNA methylation markers may be added to the available assay to improve the early detection of HCC.- Published
- 2022
- Full Text
- View/download PDF